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a  b  s  t  r  a  c  t
Allergic  asthma  represents  an  important  public  health  issue,  most  common  in the  paediatric  popula-
tion,  characterized  by airway  inﬂammation  that  may  lead  to  changes  in volatiles  secreted  via  the  lungs.
Thus,  exhaled  breath  has  potential  to be  a matrix  with  relevant  metabolomic  information  to  character-
ize  this  disease.  Progress  in  biochemistry,  health  sciences  and  related  areas  depends  on instrumental
advances,  and  a high  throughput  and  sensitive  equipment  such  as comprehensive  two-dimensional  gas
chromatography–time  of  ﬂight  mass  spectrometry  (GC  ×GC–ToFMS)  was  considered.  GC ×  GC–ToFMS
application  in  the  analysis  of  the  exhaled  breath  of  32  children  with  allergic  asthma,  from  which  10  had
also  allergic  rhinitis,  and  27  control  children  allowed  the  identiﬁcation  of  several  hundreds  of  compounds
belonging  to different  chemical  families.  Multivariate  analysis,  using  Partial  Least  Squares-Discriminant
Analysis  in tandem  with  Monte  Carlo  Cross  Validation  was  performed  to  assess  the predictive  power
and  to help  the interpretation  of  recovered  compounds  possibly  linked  to  oxidative  stress,  inﬂammation
processes  or other  cellular  processes  that  may  characterize  asthma.  The  results  suggest  that  the  modelpectrometry is robust,  considering  the  high  classiﬁcation  rate,  sensitivity,  and  speciﬁcity.  A pattern  of six  compounds
belonging  to the  alkanes  characterized  the  asthmatic  population:  nonane,  2,2,4,6,6-pentamethylheptane,
decane, 3,6-dimethyldecane,  dodecane,  and tetradecane.  To  explore  future  clinical  applications,  and  con-
sidering  the future  role  of  molecular-based  methodologies,  a compound  set was  established  to  rapid
access of information  from  exhaled  breath,  reducing  the  time  of  data  processing,  and  thus,  becoming
r  themore  expedite  method  fo
. Introduction
Asthma is a complex inﬂammatory disorder characterized
y allergic inﬂammation, smooth muscle contraction, bronchial
yperresponsiveness, hypertrophy and hyperplasia of smooth
uscle, hypersecretion of bronchial mucus, activation of mast cells,
osinophils, lymphocytes, epithelial cells, macrophages, disruption
f the bronchial epithelium and production of free radicals with
ariable symptoms (e.g. cough, dyspnoea, wheezing, chest pain) [1].
llergic asthma is the most common form of asthma and is increas-
ng considerably, in developed countries such that it is now one of
he commonest chronic disorders in the world, and is also associ-
ted with high direct and indirect health costs, especially related
ith diagnosis and treatment.
In recent years, non-invasive techniques that may  be useful
or the assessment of airway inﬂammation have been found in
he analysis of exhaled breath. Inﬂammation plays a critical role
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in many physiological changes of the body including inﬂamma-
tory lung diseases like asthma. Inﬂammation is accompanied by
oxidative stress and subsequently lipid peroxidation and during
this process polyunsaturated fatty acids are converted into volatiles
that are secreted via the lungs. Hundreds of different volatiles are
present in human breath, and their relative concentrations may
alter via the disease [2]. Exhaled breath has been studied using
one-dimensional gas chromatographic (1D-GC) process in lung dis-
eases, such as asthma [2,3], cystic ﬁbrosis [4] and lung cancer [5,6].
Although such approach often provides satisfying analytical results
an in-depth chromatogram analysis frequently indicates that some
peaks are the result of two or more co-eluting compounds. Compre-
hensive two  dimensional gas chromatography (GC × GC) employs
two orthogonal mechanisms to separate the constituents of the
sample within a single analysis, based on the application of two  GC
columns coated with different stationary phases, which increases
peak capacity as a result of the product of the peak capacity of
the two dimensions. For example, a non-polar/polar phase com-
bination (NP/P), connected in series through a modulator interface
achieves this goal. For instance, using a cryogenic modulator, the
interface samples small (several seconds) portions of the ﬁrst
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Table 1
Characteristics of the studied population: allergic asthma and control children.
Allergic asthma (n = 32) Control (n = 27)
Age in years (range/median) 4–16/9 3–6/5
Gender (male/female) 18/14 15/12
Pathology
Allergic asthma (AA) 22 (69%) –
Allergic asthma + allergic rhinitis (AA + AR) 10 (31%) –
Allergensa
Dust mite 18 (56%) –
Dust mite + gramineae 5 (16%) –
Gramineae 4 (13%) –
Dust mite + cat fur + gramineae 2 (6%) –
Dust mite + cat fur 1 (3%) –
Gramineae + cat fur 1 (3%) –
Dust mite + cockroach 1 (3%) –
Therapy
Corticosteroid Leukotriene receptor antagonist Bronchodilator Anti-histamine Nasal corticosteroid Allergic asthma (n = 32) Control (n = 27)
x x x – – 1 (3%) –
x  – x – – 9 (28%) –
x  x – – – 5 (16%) –
–  x – x x 2 (6%) –
– – x x – 5 (16%) –
–  x x – – 1 (3%) –
– – –  x x 2 (6%) –
–  x – x – 1 (3%) –
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a Results obtained by prick-tests.
imension (1D) eluate by cryofocusing, and re-injects them into
he second column (2D). Each 1D peak is modulated several times,
argely preservating the 1D separation. Co-eluting compounds from
D undergo additional separation on 2D [7].  Sensitivity and limits of
etection are improved due to focusing of the peak in the modulator
nd separation of analytes from chemical background [8] compared
o 1D-GC. ToFMS (time-of-ﬂight mass spectrometry) brings several
dvantages such as full mass spectra acquisition at trace level sensi-
ivity and mass spectral continuity, which allows for deconvolution
f spectra of co-eluted peaks [9].  To the best of our knowledge,
C × GC–ToFMS methodology has never been reported before to
tudy allergic asthma exhaled breath volatile composition. How-
ver, GC × GC–ToFMS has been used with multibed sorption trap
or exploring human exhaled breath volatile composition [10], and
earching potential biomarkers for active smoking [11], and com-
ined with automated needle trap for breath analysis of patients
ndergoing cardiac surgery [12]. These studies revealed the poten-
ial of this technique in breath analysis. Thus, this study aims to
btain a deeper knowledge of allergic asthma based on exhaled
reath analysis using a previously developed HS-SPME extraction
echnique, as well as several other exhaled breath sampling param-
ters [3],  combined with GC × GC–ToFMS system. The ﬁrst step
as to check the separation potential of GC × GC–ToFMS and sen-
itivity issues, important parameters in exhaled breath analysis,
 complex matrix with several compounds in the micromolar to
anomolar range [13]. Secondly, Partial Least Squares-Discriminant
nalysis (PLS-DA) and Monte Carlo Cross Validation (MCCV) were
erformed to assess both the predictive power and classiﬁcation
odels robustness. Moreover PLS-DA regression vectors were used
o help understand metabolic variations important to class discrim-
nation.
. Experimental.1. Standards and materials
Several reagents were used to perform this study: linear alka-
es (C8–C20) in hexane (99.5%, Fluka, Madrid, Spain), linear alkenes6 (19%)
(C8–C20) (98%, Sigma–Aldrich, Madrid, Spain), aldehydes: hexanal
(98%, Sigma–Aldrich, Madrid, Spain), (E)-2-nonenal (95%, Acros
Organics, Geel Belgium), decanal (98%, Sigma–Aldrich, Madrid,
Spain), ketones: 3-heptanone (97%, Sigma–Aldrich, Madrid, Spain),
5-methyl-3-heptanone (94%, Sigma–Aldrich, Madrid, Spain), 3-
octanone (98%, Sigma–Aldrich, Madrid, Spain), absolute ethanol
was supplied by Panreac (99.5%, analytical grade, Barcelone, Spain).
Ultra pure water was obtained from a Milli-Q system from Millipore
(Milford, MA,  USA).
For the sensitivity studies, a stock solution of each standard
(1 g/L) was  prepared in absolute ethanol and made up to volume,
and from this a solution of 100 mg/L was  set up. A working solution
was prepared to yield different concentrations and to reproduce a
two-phase system (headspace and coating ﬁbre), as in breath anal-
ysis, 5 L was  added to a 120 mL  SPME ﬂask and sealed with an
aluminium crimp cap with a vial was  capped with a PTFE septum
(Chromacol, Hertfordshire, UK), and concentrations ranged from 20
to 200 × 103 pg/L.
The SPME holder for manual sampling and ﬁbre were pur-
chased from Supelco (Aldrich, Bellefonte, PA, USA). The SPME
device included a fused silica ﬁbre coating partially cross-linked
with 50/30 m divinylbenzene-carboxen-poly(dimethylsiloxane)
(DVB/CAR/PDMS). Prior to use, the SPME ﬁbre was conditioned at
270 ◦C for 60 min  in the GC injector, according to the manufacturer’s
recommendations. Then, the ﬁbre was  daily conditioned for 10 min
at 250 ◦C.
2.2. Samples
A group of 32 children with allergic asthma, from which 10 had
allergic asthma and allergic rhinitis, and 27 healthy control chil-
dren volunteered for this study (n = 59). The characteristics of the
patients and controls are presented in Table 1. A naive patient was
also included in this study. This patient was  a 9 years old female
child that had never taken an asthma drug and was diagnosed
by physicians with allergic asthma based on symptoms history
and skin prick tests were performed being positive for dust mites.
After the ﬁrst consult, this child was  prescribed a combination
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f anti-histamine and a leukotriene receptor antagonist. The 59
ndividuals correspond to a total of 69 exhaled breath samples. Usu-
lly, each individual corresponds to one breath sample, except for
n allergic asthma child that was collected up to 6 times in differ-
nt locations/time periods and for the naive exhaled breath was
ollected at four different moments.
All parents signed an informed consent for participation in the
tudy. The children with allergic asthma were recruited from the
utpatient clinic of paediatric immunoalergology and from the
mmunoalergology departments of the Hospital Infante D. Pedro
.P.E (Aveiro, Portugal) whilst healthy controls were recruited at
wo local daycare facilities that presented no asthma episodes or
ymptoms. Asthma diagnosis was made based on clinical symp-
oms and exams (skin prick tests and IgE values). Appropriate
herapy was prescribed by the patient’s own physician. The allergic
sthma population represented a controlled asthma status, with
xception of a naive child (see Section 3.3). No restrictions were
pplied regarding drugs or diet, and each allergic asthma and con-
rol groups were sampled in two distinct locations (in a total of four
ollections sites). The study was approved by the hospital ethics
ommittee and the daycare administration.
.3. Breath sampling
The breath sampling parameters were previously optimized [3].
xhaled breath was collected in 1 L Tedlar® bags. Children were
sked to cleanse their mouth with water before sampling. Subse-
uently, children were instructed to inhale and exhaled normally
nd then exhale deeply into the Tedlar® bag previously holding
heir breath for 5 s. The collection method was successfully done
y all volunteers. Each subject provided one sample using a dispos-
ble mouthpiece. Before collecting exhaled breath, all bags were
horoughly cleaned to remove residual contaminants by ﬂushing
ith high purity nitrogen gas. The bags were transported to the
aboratory and the analysis was performed to a maximum of six
ours as recommended by Mochalski et al. [14]. On average, the
nalysis was performed after 2–3 h after sampling. The bags were
tored at 22 ◦C.
.4. HS-SPME methodology
The SPME coating ﬁbre and the experimental parameters were
dopted from a methodology previously developed in our labo-
atory [3]: DVB/CAR/PDMS ﬁbre, and an extraction temperature
nd time of 22 ◦C and 60 min, respectively. Following the extrac-
ion procedure, the SPME ﬁbre was retracted from the Tedlar®
ag and inserted in the GC system injection port. The HS-SPME
ethodology was also applied to selected standards to verify the
C × GC sensitivity as previously described in Section 2.1.  Each
reath represents a single sample, and was analysed once. To verify
he absence of any carry over, blanks (that corresponds to the anal-
sis of the coating ﬁbre not submitted to any extraction procedure
nd Tedlar® bags) were performed.
.5. GC × GC–ToFMS analysis
After the extraction/concentration step, the SPME coating ﬁbre
as manually introduced into the GC × GC–ToFMS injection port
t 250 ◦C. The injection port was lined with a 0.75 mm I.D. split-
ess glass liner. Splitless injections were used (2 min). LECO Pegasus
D (LECO, St. Joseph, MI,  USA) GC × GC–ToFMS system consisted
f an Agilent GC 7890A gas chromatograph, with a dual stage
et cryogenic modulator (licensed from Zoex) and a secondary
ven. The detector was a high-speed ToF mass spectrometer. An
P-5 column (30 m ×0.32 mm I.D., 0.25 m ﬁlm thickness, 5%
henyl-methylpolysiloxane, J&W Scientiﬁc Inc., Folsom, CA, USA)r. A 1254 (2012) 87– 97 89
was used as 1D column and a DB-FFAP (0.79 m × 0.25 mm  I.D.,
0.25 m ﬁlm thickness, nitroterephthalic acid modiﬁed polyethy-
lene glycol, J&W Scientiﬁc Inc., Folsom, CA, USA) was used as 2D
column. The carrier gas was  helium at a constant ﬂow rate of
2.50 mL/min. The GC × GC–ToFMS injection port was at 250 ◦C. The
primary oven temperature programme was: initial temperature
35 ◦C (hold 1 min), raised to 40 ◦C (1 ◦C/min), and ﬁnally rose to
220 ◦C (7 ◦C/min) and hold for 1 min. The secondary oven temper-
ature programme was 15 ◦C offset above the primary oven. The MS
transfer line temperature was  250 ◦C and the MS  source temper-
ature was  250 ◦C. A 6 s modulation time with a 30 ◦C secondary
oven temperature offset (above primary oven) was chosen to be
a suitable compromise as it maintained the 1D separation, max-
imized the 2D resolution, and avoiding wrap-around effect (the
elution time of a pulsed solute exceeds the modulation period) for
compounds that were late to elute from the 2D. Ideally, all peaks
must be detected before the subsequent re-injection and, hence,
2tR must be equal or less than the modulation period [15,16]. The
ToFMS was  operated at a spectrum storage rate of 125 spectra/s.
The mass spectrometer was operated in the EI mode at 70 eV using
a range of m/z 35–350 and the detector voltage was  −1695 V. Total
ion chromatograms (TIC) were processed using the automated data
processing software ChromaToF (LECO) at signal-to-noise thresh-
old of 80. Contour plots were used to evaluate the separation
general quality and for manual peak identiﬁcation. In order to
identify the different compounds, the mass spectrum of each com-
pound detected was compared to those in mass spectral libraries of
one home-made (using standards) and two  commercial databases
(Wiley 275 and US National Institute of Science and Technology
(NIST) V. 2.0 – Mainlib and Replib). The identiﬁcation was also
supported by experimentally determining the retention index (RI)
values that were compared, when available, with values reported in
literature for chromatographic columns similar to that used as the
1D column and whenever available compared to RI values obtained
by GC × GC [17–52].  For determination of RI values a C8–C20 n-
alkanes series was  used, calculated according to the Van den Dool
and Kratz equation [53]. The majority (>90%) of the identiﬁed com-
pounds presented similarity matches >850. The GC × GC area data
was used as an approach to estimate the relative content of each
volatile component of exhaled breath.
2.6. Multivariate analysis
A full dataset comprises 134 metabolites belonging to selected
chemical families. A sub-set of 23 metabolites was also established
by the compounds simultaneously identiﬁed by GC × GC–ToFMS,
and those previously reported in a allergic asthma study [3] (indi-
cated in Table 2). Partial Least Squares (PLS) is a widely used
procedure for both regression and classiﬁcation purposes. Con-
cerning the classiﬁcation application of PLS, known as Partial Least
Squares-Discriminant Analysis (PLS-DA) [54], the most common
approach is to use a Y matrix containing dummy variables which
deﬁnes sample memberships to pre-deﬁned groups and allow
extracting relevant information/variability that could describe the
reasons for the observed patterns (clusters). This methodology
allows one to understand which variables (metabolites) contribute
the most for the observed separation. Each sample was  mean nor-
malized and UV (unit variance) scaled which is a data pre-treatment
process that gives to variables the same weight. The PLS-DA
was applied to volatile metabolites (both datasets: 23 and 134
metabolites) tentatively identiﬁed by HS-SPME/GC ×GC–ToFMS in
all exhaled breath samples (69) and for classiﬁcation purposes two
groups were used (control and asthma).
The classiﬁcation model complexity (number of latent variables)
of the full dataset (134 metabolites) was computed, as well as
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Table 2
List of volatile compounds identiﬁed by GC × GC–ToFMS in exhaled breath of allergic asthma and control children.
Peak number 1tR a (s) 2tR a (s) Compounds CAS number RIcalc b RIlit. c (GC) RIlit. d (GC × GC)
Alkanes
Linear and ramiﬁed
1 138 0.48 Hexane 110-54-3 600 600 600
4  210 0.52 2,4-Dimethylhexane 589-43-5 727 736 729
7  252 0.54 Octane 111-65-9 800 800 800
11  276 0.55 2,2,4-Trimethylhexanee 921-47-1 817 810 –f
12 288 0.55 2,4-Dimethylheptanee 2213-23-2 817 820 822
13 318 0.56  4-Ethyl-2-methylhexane 3074-75-7 831 833 –
15 366 0.58  Alkane isomer (m/z 43, 57, 85) – 853 – –
20 468  0.56 Nonane 111-84-2 900 900 900
22  504 0.55 Alkane isomer (m/z 43, 57, 85) – 919 – –
23  516 0.55 2,4-Dimethyloctanee 15869-93-9 925 924 –
24  528 0.56 3-Ethyl-3-methylheptanee 17302-01-1 932 – 942
26 540 0.55  2,6-Dimethyloctane 2051-30-1 938 936 933
28  552 0.55 3-Ethyl-2-methylheptane 14676-29-0 944 – 942
30 558  0.55 Alkane isomer (m/z 57, 43, 71) – 947 – –
31  564 0.55 Alkane isomer (m/z 43, 57, 71) – 950 – –
33 576 0.56  4-Ethyloctane 15869-86-0 957 956 –
36  582 0.55 4-Methylnonane 17301-94-9 960 962 956
38 588  0.54 Alkane isomer (m/z 57, 43, 85) – 963 – –
40  594 0.55 Alkane isomer (m/z 57, 43, 71) – 966 – –
42  600 0.55 2-Methylnonane 871-83-0 969 970 –
43  606 0.55 Alkane isomer (m/z 57, 43, 41) – 972 – –
45  612 0.55 3-Methylnonanee 5911-04-6 975 976 –
52 636 0.54  2,2,4,6,6-Pentamethylheptane 13475-82-6 988 997 –
58  660 0.56 Decanee 124-18-5 1000 1000 1000
60 672  0.54 Alkane isomer (m/z 57, 41, 71) – 1008 – –
61  720 0.54 3,9-Dimethylnonanee 17302-32-8 1039 1038
64  756 0.54 3,6-Dimethyldecanee 17301-30-3 1062 1063 –
66 768 0.54  Alkane isomer (m/z 57, 43, 85) – 1070 – –
68  774 0.55 3-Methyldecanee 13151-34-3 1073 1073 –
72 786 0.55  Alkane isomer (m/z 57, 43, 71) – 1081 – –
74  798 0.55 2-Methyldecanee 6975-98-0 1089 1073 –
76 804  0.55 Alkane isomer (m/z 43, 71, 57) – 1093 – –
81  822 0.55 Undecanee 1120-21-4 1100 1100 1100
84  864 0.56 2,3-Dimethyldecanee 1632-71-9 1135 1118 –
86 876 0.56  Alkane isomer (m/z 57, 43, 71) – 1144 – –
87  894 0.55 5-Methylundecanee 1632-70-8 1157 1154 –
89 906  0.57 Alkane isomer (m/z 57, 43, 71) – 1166 – –
90  912 0.57 3,9-Dimethylundecanee 7045-71-8 1170 1165 –
95  948 0.57 Dodecanee 112-40-3 1200 1200 1200
96  960 0.58 Alkane isomer (m/z 57, 71, 43) – 1206 – –
99  966 0.57 Alkane isomer (m/z 57, 43, 71) – 1211 – –
100 972 0.56 2,5,6-Trimethyldecanee 17301-28-9 1216 1206 –
101  978 0.57 Alkane isomer (m/z 57, 43, 71) – 1221 – –
104 996  0.56 Alkane isomer (m/z 57, 43, 71) – 1236 – –
106  1002 0.57 Alkane isomer (m/z 57, 43, 71) – 1241 – –
107  1008 0.57 6-Methyldodecane 6044-71-9 1246 1253 –
108  1020 0.57 Alkane isomer (m/z 43, 57, 71) – 1256 – –
110  1044 0.55 Alkane isomer (m/z 57, 43, 71) – 1276 – –
111  1050 0.55 4-Ethylundecane 17312-59-3 1281 – –
112  1056 0.57 Alkane isomer (m/z 57, 43, 71) – 1286 – –
113  1062 0.55 Alkane isomer (m/z 57, 71, 43) – 1291 – –
115  1068 0.56 Alkane isomer (m/z 43, 57, 71) – 1296 – –
117  1074 0.57 Tridecanee 629-50-5 1300 1300 1300
120  1092 0.57 2,2-Dimethyldodecane 49598-54-1 1316 1315 –
121  1104 0.57 Alkane isomer (m/z 57, 43, 71) – 1327 – –
122  1110 0.57 Alkane isomer (m/z 57, 43, 71) – 1332 – –
123  1116 0.57 Alkane isomer (m/z 57, 71, 43) – 1337 – –
124  1128 0.57 3-Ethyl-3-methylundecanee – 1348 1347 –
125  1152 0.60 2-Methyltridecanee 6418-41-3 1369 1371 –
126  1158 0.59 Alkane isomer (m/z 57, 43, 71) – 1374 – –
127  1170 0.61 Alkane isomer (m/z 57, 43, 71) – 1385 – –
128  1188 0.61 Tetradecanee 629-59-4 1400 1400 1400
130  1284 0.58 Alkane isomer (m/z 57, 43, 85) – 1489 – –
131 1290 0.58 6,6-Diethyldodecane – 1495 1498 –
132  1296 0.64 Pentadecanee 629-62-9 1500 1500 1500
133  1302 0.59 5-Ethyl-5-methyltridecane – 1507 1511 –
134  1338 0.61 3-Ethyl-3-methyltridecane – 1544 1549 –
Cycloalkanes
5 240 0.57  1,2,4-Trimethylcyclopentane 930-57-4 780 779 –
8 252  0.58 1,4-Dimethylcyclohexane 589-90-2 800 – 806
25  534 0.60 Propylcyclohexane 2040-95-1 935 929 –
34 576  0.59 1,1,2,3-Tetramethylcyclohexane 6783-92-2 953 958 –
47  618 0.60 2-Ethyl-1,3-dimethylcyclohexane 7045-67-2 978 – –
48 624  0.59 1-Methyl-3-propylcyclohexane 4291-80-9 982 – –
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Table  2 (Continued)
Peak number 1tR a (s) 2tR a (s) Compounds CAS number RIcalc b RIlit. c (GC) RIlit. d (GC × GC)
49 630 0.58 1-Methyl-3-(2-methylpropyl)cyclopentane 29053-04-1 985 – –
53  642 0.59 Ethylpropylcyclopentane 54111-97-6 991 – –
57  654 0.59 1-Methyl-2-propylcyclohexane 4291-79-6 997 – –
63 732 0.57  Hexylcyclopentane 1003-19-6 1047 – –
73  792 0.57 1,4-Dimethylcycloctane 13151-98-9 1085 – –
77 804  0.59 1-Ethyl-2-propycylohexane 62238-33-9 1093 – –
105  996 0.62 Hexylcyclohexane 4292-75-5 1236 1237 –
116  1068 0.65 1-Hexyl-3-methylcyclohexane 591-48-0 1296 – –
118  1080 0.60 1-Butyl-2-propylcyclopentane 62199-50-2 1306 – –
Alkenes
Linear
10 252  0.60 3-Octene 592-98-3 803 800 –
14  330 0.61 2,4-Dimethyl-1-heptene 19549-87-2 836 842 –
17  450 0.61 1-Nonene 124-11-8 892 889 –
27  546 0.57 Alkene isomer (m/z 55, 41, 69) – 941 – –
29  552 0.57 3-Methyl-1-nonene 2980-41-4 944 944 –
32 570  0.59 3,4-Diethyl-2-hexene 19550-82-4 957 – –
37  582 0.59 Alkene isomer (m/z 69,41,56) – 960 – –
44 606 0.59  Alkene isomer (m/z 69,41,56) – 972 – –
46  612 059 7-Methyl-1-nonene 2980-71-4 975 960 –
56 648 0.59  4-Decene 19398-89-1 994 – 994
65  762 0.55 Alkene isomer (m/z 55, 69, 41) – 1066 – –
67  768 0.56 Alkene isomer (m/z 55, 69, 41) – 1070 – –
70  780 0.56 (Z)-2-Decene 20348-51-0 1077 1072 –
75  798 0.56 Alkene isomer (m/z 55, 69, 41) – 1089 – –
79 810 0.55  Alkene isomer (m/z 69, 55, 41) – 1097 – –
83  828 0.57 Alkene isomer (m/z 55, 69, 41) – 1109 – –
85 870  0.59 2-Methyl-1-undecene 18516-37-5 1140 1144 –
92  918 0.60 (E)-5-Methyl-4-undecene 41851-94-9 1174 – –
93  924 0.60 (Z)-5-Methyl-5-undecene 57024-93-8 1179 – –
94 942 0.60  1-Dodecene 112-41-4 1192 1192 –
97  960 0.62 Alkene isomer (m/z 55, 69, 41) – 1206 – –
102 978 0.59 Alkene isomer (m/z 55, 69, 43) – 1221 – –
114  1062 0.61 1-Tridecene 2437-56-1 1291 1292 –
Aldehydes
Linear
3  144 0.78 Butanal 123-72-8 614 595 –
9 252 1.17  Hexanal 66-25-1 801 802 –
21  474 1.22 Heptanal 111-71-7 904 904 –
35 576  0.92 2-Ethylhexanal 123-05-7 957 – 957
59  666 1.06 Octanal 124-13-0 1005 1003 –
82  822 1.00 Nonanale 124-19-6 1105 1106 –
88  900 1.28 (E)-2-Nonenal 18829-56-6 1162 1164 –
98  960 0.97 Decanal 112-31-2 1206 1206 –
109 1038 1.03 Aldehyde isomer (m/z 41, 55, 71) – 1266 – –
119  1086 1.02 Undecanal 112-44-7 1311 1310 –
129 1200 1.09 Dodecanal 112-54-9 1412 1410 –
Aromatic aldehyde
39 588 3.58 Benzaldehydee 100-52-7 964 964 –
Ketones
2  138 0.79 2-Butanone 78-93-3 601 602 –
6  240 1.16 2-Hexanone 591-78-6 781 790 –
16  438 1.19 3-Heptanone 106-35-4 887 885 884
18  450 1.29 Ketone isomer (m/z  43, 58, 71) – 892 – –
54  642 1.10 3-Octanone 106-68-3 991 989 –
55  642 1.33 6-Methyl-5-hepten-2-one 110-93-0 991 989 –
78  804 1.03 2-Nonanone 821-55-6 1093 1093 –
80  810 1.02 Ketone isomer (m/z  43, 58, 71) – 1097 – –
Cyclic  ketone
19 450 2.07 Ciclohexanone 108-94-1 893 895 –
Miscellaneous
50  630 2.13 1-Octen-3-ol 3391-86-4 985 986 –
62  720 1.78 2-Ethyl-1-hexanol 104-46-7 1040 1026 –
69  774 0.99 2-Nonen-1-ol 22104-79-6 1074 1105 –
71  780 1.86 1-Octanol 111-87-5 1078 1068 –
91  912 0.97 2-Decen-1-ol 22104-80-9 1170 – –
51 630  3.78 Aniline 62-53-3 986 971 –
41  594 1.83 Dimethyl trisulﬁde 58-80-8 967 972 –
103  978 3.73 Benzothiazole 95-16-9 1223 1227 –
a Retention times in seconds (s) for ﬁrst (1tR) and second (2tR) dimensions.
b RI: retention index obtained through the modulated chromatogram.
c RI: retention index reported in the literature for one dimensional GC with a 5%-Phenyl-methylpolysiloxane GC column or equivalent [17–19,21–46,48–52].
d RI: retention index reported in the literature for a comprehensive GC × GC system with Equity-5 for the ﬁrst dimension [20,47].
e Set of 23 metabolites previously reported in a study related to allergic asthma [3] that was used in Fig. 4.
f Information not available.
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lassiﬁcation rate and Q2 were estimated by cross-validation (7
locks splits). Model robustness was assessed using MCCV with
000 iterations. For each of the 1000 randomly generated classiﬁca-
ion models, the number of latent variables (LV), the Q2 (expressing
he cross-validated explained variability), and the confusion matrix
as computed. The selection of model complexity was based on
he most frequent list of model properties that maximizes the pre-
ictive power (i.e., lower LV and higher Q2). The sensitivity and
he speciﬁcity of the model were then depicted from the confusion
atrix resulting into a ROC map  to further assess the results sig-
iﬁcance. Then, the same procedure was applied using permuted
lass membership. Sensitivity is calculated from the ratio between
rue positives (allergic asthma samples correctly predicted) and the
otal number of modelled breath samples, whereas speciﬁcity is
etermined from the ratio between true negatives (control sam-
les correctly predicted) and the total number of modelled control
C ×GC data.
. Results and discussion
A previous study [3] reported the development of an HS-
PME/GC–qMS methodology, as well as the optimization of
mportant breath sampling parameters and its application to a
roup of children with allergic asthma and controls. To increase
he information obtained on exhaled breath, in the present study
he HS-SPME technique was applied to exhaled breath of a dif-
erent population (n = 59) using a powerful tool such as the
C × GC–ToFMS, that is more sensitive, has higher chromato-
raphic resolution and a structured chromatogram is obtained,
hree relevant advantages relatively to 1D-GC analysis.
.1. Structured chromatogram and sensitivity
GC × GC has proven to be a powerful technique in the analysis
f complex samples and to detect trace components [55,56]. Auto-
ated processing of HS-SPME/GC × GC–ToFMS data was  used to
entatively identify all peaks in the GC × GC chromatogram contour
lots with signal-to-noise threshold > 80. The peak ﬁnding routine
ased on deconvolution method allowed to identify ca. 350 com-
ounds per sample comprising several chemical families: linear
nd ramiﬁed alkanes, cycloalkanes, alkenes, aldehydes, ketones,
romatic compounds, terpenoids and esters. From these, 134 com-
ounds belonging to linear, ramiﬁed and cycloalkanes, alkenes,
ldehydes, ketones and a group of miscellaneous compounds,
ere selected for further studies. The remaining compounds
ere considered as possible contaminants, as for example, aro-
atic compounds from environmental cumulative exposure [57],
hereas terpenoids and esters can have its origin in ingested foods
58]. Otherwise, the linear, ramiﬁed and cycloalkanes, alkenes,
ldehydes and ketones have been reported to be associated to sev-
ral biochemical processes that may  occur in humans [59].
The total number of compounds detected in allergic asthma
xhaled breath substantially increased with the use of the
C × GC–ToFMS, approximately 8 times, when compared to the
btained results by 1D-GC-qMS [3].  By 1D-GC-qMS a total of 44
ompounds were identiﬁed whereas by GC × GC–ToFMS ca. 350
ompounds were tentatively identiﬁed. For example, consider-
ng the alkanes, alkenes, aldehydes and ketones, the number of
etected compounds increased by 66%, 96%, 67% and 56%, respec-
ively.
The compounds included in the selected dataset were tenta-
ively identiﬁed based on comparison of their mass spectra to
ome-made and commercial databases (MS), and by comparison
f the RIs calculated (RIcalc) with the values reported in the litera-
ure (RIlit) for 5% phenylpolysilphenylene-siloxane (or equivalent)Fig. 1. Peak apex plot of the alkanes (linear, ramiﬁed and cyclic), alkenes, aldehydes
and ketones identiﬁed using allergic asthma exhaled breath sample.
column (Table 2). A range between 1 and 30 was obtained for RIcal
compared to the RIlit reported in the literature (|RIcalc − RIlit|) for
1D-GC with 5%-phenyl-methylpolysiloxane GC column or equiva-
lent. This difference in RI is considered minimal (on average lower
than 0.5%), and is well justiﬁed if one takes into account that: (i)
the literature data is obtained from a large range of GC station-
ary phases (several commercial GC columns are composed of 5%
phenylpolysilphenylene-siloxane or equivalent stationary phases),
and (ii) the literature values were determined in a 1D-GC separa-
tion system, and the modulation causes some inaccuracy in ﬁrst
dimension retention time [56].
The most reliable way  to conﬁrm the identiﬁcation of each com-
pound is based on authentic standard co-injection, which in several
cases is economically prohibitive, and often unachievable in the
time available for analysis [60], or are not commercially available.
Thus, GC × GC is an ideal technique for the analysis of complex mix-
tures where compounds of similar chemical structure are grouped
into distinct patterns in the 2D chromatographic plane providing
useful information on both their boiling point and polarity (if NP/P
set of columns was  used), and relationships of structured reten-
tions have proved especially useful for compound identiﬁcation
[61]. To demonstrate the structured chromatogram a chromato-
graphic space with higher peak density, ranging between 2tR 0.45
and 1.45 s, was chosen, and a peak apex plot was depicted regard-
ing the alkanes, alkenes, aldehydes and ketones to better visualise
the attained structured chromatogram (Fig. 1). The components of
each chemical group were dispersed through the peak apex plot
according to their volatility (1D) and polarity (2D) obtained by
a combination of NP/P columns. For the selected chemical fami-
lies, as expected, it was  observed that the decrease in volatility
(high 1tR) is mainly related to the increase in the number of car-
bons. The structured 2D chromatographic proﬁle was  observed
within each chemical family based on the properties and posi-
tions of their functional groups. Globally, based on the functional
group of the chemical families under study, the 2tR values increase
as follows: alkanes < alkenes ∼ cycloalkanes < ketones ∼ aldehydes.
This information can be also conﬁrmed in Table 2. Alka-
nes have the lowest polarity (2tR ∼=0.48 − 0.64 s), followed
by alkenes (2tR ∼=0.57 − 0.62 s), cycloalkanes (2tR ∼=0.57 − 0.65 s),
ketones (2tR ∼=0.79 − 1.33 s), and aldehydes (2tR ∼=0.78 − 3.58 s).
This information is especially useful for classifying unidentiﬁed
compounds.
A further advantage of a comprehensive chromatographic sys-
tem can be veriﬁed, as compounds with similar boiling points that
could co-elute in a 1D system, as for example 4-ethyloctane (33),
1,1,2,3-tetramethylcyclohexane (34) and 2-ethylhexanal (35) [3],
are able to be separated using the comprehensive chromatographic
system (Fig. 2). These compounds have similar volatility, the same
1tR of 576 s but present different polarities, and as a consequence
M. Caldeira et al. / J. Chromatog
Fig. 2. Blow-up of a part of total ion GC × GC chromatogram contour plot
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Fbtained from an allergic asthma exhaled breath showing the corresponding
amiﬁed alkane, cycloalkane and ramiﬁed aldehyde: 4-ethyloctane (33), 1,1,2,3-
etramethylcyclohexane (34) and 2-ethylhexanal (35), respectively.
hey were separated by the second column (2tR of 0.56, 0.59 and
.92 s, respectively).
Different concentrations, ranging from nmolar to molar have
een reported for volatile breath components [13,62], so an impor-
ant issue is the sensitivity of the used equipment. Consequently,
he GC × GC–ToFMS sensitivity was veriﬁed, and for this purpose
 standard solution comprising standards pertaining to the previ-
usly selected families (alkanes, alkenes, aldehydes and ketones)
as used, whose concentration, for instance, varied between
0 pg/L to 200 ng/L. The standards from the tested compound fam-
lies were detected at the level under study (data not shown).
or demonstration purposes, 1-dodecene (94) and dodecane (95),
howed in Fig. 3, were detected at pg/L and ng/L levels. The stud-
ed range was lower than the reported values to verify that this
quipment is able to detect compounds at this concentration level,
hich could be relevant to identify target compounds that could
e important for asthma metabolomic studies.
.2. Multivariate analysis in the establishment of asthma
breath-print”
In the previous study [3],  28 compounds, from a total of 44, were
elected and distinction was achieved with two relatively deﬁned
ig. 3. Total ion GC ×GC chromatogram and corresponding contour plots of 1-dodecene (r. A 1254 (2012) 87– 97 93
clusters between the control and the allergic asthma groups. As
a ﬁrst approach, using a different allergic asthma and control chil-
dren population, from the 28 compounds identiﬁed by GC–qMS [3],
23 were also identiﬁed by GC × GC–ToFMS and selected for multi-
variate analysis (indicated in Table 2) to verify the results obtained
in the previous study. PLS-DA was applied to the GC × GC chro-
matographic unit variance scaled areas to establish a preliminary
classiﬁcation model and assess the relationships between the com-
pounds and the samples under study. Fig. 4A shows that there are
two deﬁned clusters with the control group being mainly associated
to LV1 negative values and the allergic asthma group to LV1 positive
values. From the previous study [3],  the allergic asthma group was
mainly characterized by decane, dodecane and tetradecane, which
were conﬁrmed with this new set of children (Fig. 4B).
However a clear distinction was  sought, thus PLS-DA was
applied to the full dataset of 134 metabolites identiﬁed by
GC ×GC–ToFMS. The results obtained are shown in Fig. 5A that
presents the scores scatter plot of the ﬁrst two Latent Variables
(LV1 × LV2), while Fig. 5B (corresponding LV1 loading weights plot)
establishes the contribution of each volatile metabolite that pro-
motes the observed distinction. According to MCCV statistics, the
PLS-DA model had a classiﬁcation rate of 98% and showed 96%
sensitivity (∼=4% allergic asthma children being misclassiﬁed as con-
trols) and 95% speciﬁcity (∼=5% of false positives). The most frequent
Q2 value was around 0.9 (Fig. 6), with a large prevalence of values in
the range of 0.8–1. These results suggest that confounding factors,
such as, ambient air, gender or age seems to have no signiﬁcance
in the distinction power.
Scores scatter plot (Fig. 5A) shows that the control group is asso-
ciated to LV1 negative values whereas the allergic asthma group
is linked to positive LV1 values. As observed in Fig. 5B, nonane,
2,2,4,6,6-pentamethylheptane, decane, 3,6-dimethyldecane, dode-
cane, and tetradecane are related to the allergic asthma group.
The control group is mainly characterized by 6-methyl-5-hepten-
2-one, 1-dodecene, nonanal, decanal, and dodecanal. Comparing
these results to the previous study [3],  there was an increase in the
number of compounds that characterize allergic asthma and con-
trol samples. Interestingly the controls are characterized mainly by
aldehydes and the asthmatic children are characterized by alka-
nes, namely those that arise from the corresponding aldehydes.
Hence a pattern seems to be noticeable that mainly involves these
two chemical families. The behaviour shown in the control group
has also been reported by Corradi et al. [63] as nonanal had lower
94) and dodecane (95) varying the concentration from 20 (A) to 200 × 103 pg/L (B).
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of  exhaled breath for allergic asthma and control children using a sub-set of 23
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previous assertion that a pattern of alkanes and aldehydes clearlyo allergic asthma [7] (peak attribution shown in Table 2).
alues in exhaled breath condensate of children with exacerbated
sthma (before and after treatment) when compared to control. The
ehaviour of the remaining aldehydes compounds that have higher
eight in the control group has not been previously described.
A relevant aspect brought by the results is that from the 67 iden-
iﬁed alkanes 19 are methylated, which corresponds to 28% of this
hemical family and from these, two methylated compounds, as for
xample 2,2,4,6,6-pentamethylheptane and 3,6-dimethyldecane
ave a major contribution in the observed distinction. The methy-
ated alkanes family have also been previously reported as these
ay  well be important in asthma characterization [2,64].  These
ompounds also have an important role in diseases, in which oxida-
ive stress apparently may  be involved, but to other extents, and
ith different consequences than asthma, such as lung and breast
ancer, as well as in lung cancer cell lines [65–67].  These com-
ounds have been reported in literature in other exhaled breath
tudies associated to pathological states of the lungs, but as indi-
idual markers. For example, 2,2,4,6,6-pentamethylheptane and
ecane were identiﬁed and compared by Poli et al. [68] in exhaled
reath of patients with non-small lung cancer (NSLC), chronic
bstructive pulmonary disease (COPD), smokers and controls and
heir concentrations were higher for NSLC, COPD and smokers
hen compared to controls. Dodecane has been proposed as lung
ancer markers [69,70].
These results evidence that overall, for the allergic asthma
roup, there is a greater weight of the alkanes conﬁrming the pre-
ious study [3] whereas aldehydes have a major importance in
he characterization of the control group. Alkanes, in the sequencer. A 1254 (2012) 87– 97
of oxidation reactions, are end-compounds that have been associ-
ated to oxidative stress and inﬂammation processes [71] and the
hypothesis formed is that these compounds indicate that the oxida-
tive state is at a higher extent in asthmatics when compared to
controls leading to the obtained differences and consequently the
alkanes can be associated to allergic asthma. These particular com-
pounds can be formed in the inﬂammatory response induced by the
immune system that leads to the production of activated leukocytes
causing the cells to uptake oxygen releasing reactive oxygen species
which can damage lung tissue contributing to elevated oxidative
stress in asthma [72] and there is evidence that alkanes can arise
as products of lipid peroxidation of unsaturated fats [73]. Lipid
metabolism and oxidative metabolism in the mitochondria have
been reported recently to be altered in urine of asthma patients [74]
and a conjecture could be made that this alteration shown in urine
can also be noticed in exhaled breath, considering the alkanes as a
measurement of lipid and oxidative metabolism that characterize
the allergic asthma group.
3.3. “Breath-print” exploration as a potential aid to the clinical
practice
Therapy monitoring is one of the challenges of actual medicine
as patients may  or may not follow treatment as prescribed by the
physician. To test the hypothesis that a change would occur in the
exhaled breath composition with the intake of the prescribed medi-
cation, a naive patient (patient that had never taken an asthma drug)
was recruited. This naive patient was  diagnosed by physician as
having allergic asthma, and exhaled breath was collected previous
medication intake and three other moments after intake. The med-
ication that was  prescribed was  the combination of anti-histamine
and a leukotriene receptor antagonist. Anti-histamines are drugs
that inhibit the action of histamine whereas leukotriene receptor
antagonist inhibits leukotrienes that are compounds produced by
the immune system that cause inﬂammation. This therapy combi-
nation directed to block the effects of histamine and leukotriene
mediators was  performed as it is shown that it is better than stand-
alone therapy [75]. The behaviour of a naive child was monitored
throughout 24 days (Fig. 5A, marked by the path trajectory). Ini-
tially and after 18 days after the intake of the prescribed drugs,
the naive individual remains in LV1 positive values but far from
the remaining controlled subjects. There is an evolution through-
out LV1 axis with treatment administration explained by the area
reduction of nonane, 2,2,4,6,6-pentamethylheptane, decane, 3,6-
dimethyldecane, and tetradecane. Considering that asthma crisis
is mainly characterized by inﬂammation, which is accompanied
by oxidative stress and subsequently lipid peroxidation, and that
alkanes are evidence of these biochemical processes, the observed
decrease may be due to a lesser inﬂammation state of this subject
leading to lower areas of these compounds. Clinically, the child in
the initial stages was in a crisis situation almost in a daily basis and
throughout the 24 days there was a signiﬁcant improvement of the
asthma status control.
As veriﬁed, the obtained “breath-print” allowed the distinction
between allergic asthmatic and control children which could be
helpful in understanding this pathology through a better insight
into the metabolic pathways that may  be associated to this con-
dition. Nevertheless, for clinical purposes, and having in mind the
future of molecular diagnosis, a smaller set of compounds is nec-
essary to allow a rapid use of exhaled breath for complementary
purposes in diagnosis, to follow the disease status and/or the med-
ication effect. For this intent, and taking into consideration thedeﬁnes both populations under study, just 9 compounds (nonane,
2,2,4,6,6-pentamethylheptane, decane, 3,6-dimethyldecane, dode-
cane, tetradecane, nonanal, decanal, and dodecanal) were selected
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ig. 6. Q2 values distribution of the original and permuted Monte-Carlo Cross Vali-
ation for PLS-DA of exhaled breath of full dataset (134 metabolites).for a new PLS-DA model. The results are shown in Fig. 7A and the
chosen pattern was  able to discriminate both groups showing the
exhaled breath testing is a tool that can be used as non-invasive
diagnostic method for allergic asthma. To assess both the predic-
tive power and classiﬁcation model robustness, MCCV was also
performed, using similar conditions to the previous test. Accord-
ing to MCCV statistics, the PLS-DA model had a classiﬁcation rate
of 96% and showed 98% sensitivity (∼=2% allergic asthma children
being misclassiﬁed as controls) and 93% speciﬁcity (∼=7% of false
positives). The most frequent Q2 value was around 0.8 (Fig. 8),
with a large prevalence of values in the range of 0.7–0.9. Classi-
ﬁcation rate and speciﬁcity were slightly lower than those obtain
for the full dataset, but, still, remained high. The sensitivity was
improved. These results suggest that the model is robust, even
using this set of 9 metabolites, reducing the time of data pro-
cessing, and thus, becoming more expedite method for the clinical
purposes.
A remarkable result observed in Fig. 7 is shown by the path of
the naive child (a through d – four breath sampling), which sug-
gest the mitigation of asthma symptoms following drug intake.
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cimethyldecane (64), dodecane (95), tetradecane (128), nonanal (82), decanal (98),
odecanal (129). Path of the naive child – a through d – four breath sampling.
his suggests the application of exhaled breath analysis, not only
or metabolomic proﬁling of allergic asthma, but also in clinical
ractice as a possible surrogate to the invasive diagnosis tests per-
ormed actually.
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4. Conclusions
In this study, the development of the ﬁrst
HS–SPME/GC × GC–ToFMS methodology was reported for the
analysis of exhaled breath of allergic asthma children and the
advantages of comprehensive chromatography was explored in
issues such as the structured chromatogram and sensitivity. The
structured 2D chromatogram that arose from 1D volatility and 2D
polarity was  shown and sensitivity was assessed. A well-deﬁned
chromatographic space was  obtained with the resulting structured
chromatogram, which can aid posterior exhaled breath analysis for
example in the identiﬁcation of otherwise unknown compounds.
Subsequently, the potentiality of the GC × GC–ToFMS was veriﬁed
in exhaled breath samples from allergic asthma and control
children.
The methodology allowed the identiﬁcation of several hun-
dred compounds pertaining to different chemical families (linear
and ramiﬁed alkanes, cycloalkanes, alkenes, aldehydes, ketones,
aromatic compounds, terpenoids and esters). Multivariate analy-
sis was  performed by PLS-DA to a group of selected compounds
pertaining to alkanes, alkenes, aldehydes, and ketones and the
GC ×GC–ToFMS showed to be advantageous as distinction between
both groups was  attained and a high classiﬁcation rate was
achieved. The obtained “breath-print” allowed the discrimina-
tion between allergic asthmatic and control children, providing
insights into the metabolic pathways that may be associated to
allergic asthma. In general, a pattern of six compounds pertaining
to the alkanes characterized the asthmatic population: 3,6-
dimethyldecane, nonane, 2,2,4,6,6-pentamethylheptane, decane,
dodecane, and tetradecane. Otherwise, a set of aldehydes (nonanal,
decanal, and dodecanal) characterizes the control population. Thus,
a smaller set of 9 compounds comprising alkanes and aldehydes
was chosen to verify the potential clinical usefulness of exhaled
breath for allergic asthma evaluation and the obtained results are
very satisfactory as, with this set, distinction was obtained. It was
also conﬁrmed that it is also possible to follow through the effects
of medication.
Exhaled breath metabolome presents itself as a challenge, and
in our opinion, GC × GC–ToFMS offers advantages that were veri-
ﬁed in the present study that corresponded to the challenge. This
new methodological approach to characterize allergic asthma as a
function of its metabolomic patterns will enhance the possibility of
further allergic asthma pathways knowledge. It also provides with
an easier methodology combined with a non-invasive sampling
for allergic respiratory disease assessment, regarding diagnostic,
prognostic and treatment follow-up. Further studies with a larger
population are necessary to conﬁrm these ﬁndings.
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